简体中文English

FKHR (13q14) gene breakage probe reagent
Wholesale Price(RMB):

30006000330066003300660036007200

Product Code:R-0501241Ⅰ-01/R-0501241Ⅰ-02/R-0501241Ⅱ-01/R-0501241Ⅱ-02/R-0501241Ⅲ-01/R-0501241Ⅲ-02/R-0501241Ⅳ-01/R-0501241Ⅳ-02
Probe name:GSP FKHR(Centromere)/ GSP FKHR(Telomere)
Product Code:Type I (direct FISH method)/Type II (biotin-labeled indirect FISH method)/Type III (digoxigenin-labeled indirect FISH method)/Type IV (TSA-FISH method)
Registration Number:
Clinical Value

Rhabdomyosarcoma (RMS) is a common malignancy among soft tissue tumors in children, and the prognosis is related to the primary site of the tumor, pathological staging, and the extent of the lesion (stage). The prognosis of vesicular and pleomorphic tumors is poor, and the prognosis of embryonal tumors is moderate.


Specific chromosomal translocations t(2;13)(q35;q14) and t(1;13)(p36;q14) are detected in 70% to 80% of adenoid rhabdomyosarcomas (ARMS), and the two translocations form the corresponding fusion genes PAX3-FKHR (about 75%) and PAX7-FKHR (about 25%), respectively; these two chromosomal translocations are not seen in embryonal rhabdomyosarcomas. these two chromosomal translocations.


In addition, it is difficult to perform the differentiation of ARMS from some small round cell tumors by histological analysis; therefore, FKHR (FOXO1) rearrangement detection is beneficial for the typing of rhabdomyosarcoma.